
Ethics		Project Site R&D	Date of First Patient	
Committee Ref	Project Title	Submission	Consented	Benchmark Met or Reason for Delay
	Pharmacokinetic variation and toxicity in Ewing's sarcoma (PK			Delays due to external factors outside the
13/NE/0225	2013 01)	20/06/2014		control of the Sponsor and Trust
14/YH/0048	Apposition V	23/06/2014	09/07/2014	Benchmark met
13/EE/0397	NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer) WA29231- LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN	01/07/2014	18/12/2014	Delays due to external factors outside the control of the Sponsor and Trust
	PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC		4.5 /07 /004.4	
14/NE/0122	JUVENILE IDIOPATHIC ARTHRITIS	11/06/2014	16/07/2014	Benchmark met Delays due to external factors outside the
13/LO/0716	CCRN 2159 (Uveitis)	25/06/2014		control of the Sponsor and Trust
13/LO/0717	CL3-78989-006. EYEGUARD-C study	25/06/2014	28/01/2015	Delays due to external factors outside the control of the Sponsor and Trust
13/LO/1608	Study of efficacy and safety of nilotinib in paediatric CML patients	07/07/2014	16/12/2014	Delays due to external factors outside the control of the Sponsor and Trust Delays due to external factors outside the
14/EM/0034	NCRN3025 - GDC-0199 in CLL (GO28667) - MURANO	16/07/2014	22/10/2014	control of the Sponsor and Trust
13/LO/1329	3H (Hemodiafiltration, Heart and Heights) study	28/07/2014		Benchmark met
	InterAACT - A Multicentre Randomised Phase II Advanced Anal			Delays due to external factors outside the
13/LO/1463	Cancer Trial	14/08/2014		control of the Sponsor and Trust
14/EE/0105	EORTC protocol 26101	19/08/2014	15/09/2014	Benchmark met
13/NW/0702	ABC-06: ASC alone or with mFOLFOX for advanced biliary tract cancer	20/08/2014	10/12/2014	Delays due to external factors outside the control of the Sponsor and Trust
14/NW/0008	GO-COLITIS	26/08/2014	23/12/2014	Reasons for delay rest with the Sponsor
13/LO/1515	Predicting Language Outcome & Recovery after Stroke	26/08/2014		Benchmark met
14/LO/0203	CLARITY	28/08/2014	01/10/2014	Benchmark met
12/514/0205	Treatment of Advanced Clausers Study (TACS)	04/00/2014	12/02/2015	Delays due to external factors outside the
13/EM/0395	Treatment of Advanced Glaucoma Study (TAGS) The effect of Plasma Rich in Growth Factors (PRGF) on periodontal			control of the Sponsor and Trust
14/SW/0114	tissue regeneration NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage	28/08/2014	01/10/2014	Benchmark met Delays due to external factors outside the
14/EM/0130	Chemotherapy	15/09/2014	08/01/2015	control of the Sponsor and Trust
				Delays due to external factors outside the
13/EE/0367	CCRN 2215 (Crohn's)	05/09/2014		control of the Sponsor and Trust
13/EM/0149	15961 GadaCAD1	18/09/2014 29/09/2014		Reasons for delay rest with the Trust Benchmark met
14/WM/0159 12/NW/0790	The SNIFFLE 2 Study The BASICS Trial	03/10/2014		Benchmark met
14/NW/1256	RVENCH	29/09/2014		Benchmark met
11/H1307/6	SWITCH	14/10/2014		Benchmark met
13/SC/0619	Group B streptococcus Immunisation Attitudes	01/10/2014	23/10/2014	Benchmark met
13/EM/0154	SWIFFT Trial	04/09/2014		Benchmark met
14/NS/0089	Нір 'Ор	17/10/2014		Delays due to external factors outside the control of the Sponsor and Trust
14/SC/0221	CONCEPT: A Phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of Her2 negative metastatic breast cancer (mBC)	21/10/2014	18/12/2014	Benchmark met
	AZD9291 v chemotherapy in NSCLC, following EGFR TKI therapy			Delays due to external factors outside the
14/EE/1063	(AURA3)	29/10/2014	13/01/2015	control of the Sponsor and Trust
12/50/0007	An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a	02/11/2014	28/11/2014	Bonshmark met
13/SC/0007 12/WM/0187	Dose Expansion Phase in Patients With Unresectable Melanoma. ROCSS	03/11/2014		Benchmark met Benchmark met
L2/WW/0187	OTO-104 in Meniere's Disease	13/11/2014		Benchmark met
, ,	The effect of Plasma Rich in Growth Factors (PRGF) on the	-,, -014	,, _014	
14/SW/1101	treatment of dry sockets	03/11/2014	24/11/2014	Benchmark met
14/WM/0085	Robot Assisted Fracture Surgery (RAFS)	12/11/2014	19/12/2014	Benchmark met
14/SC/1014	CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in pancreatic adenocarcinoma	20/11/2014	21/01/2015	Benchmark met
		. ,		Delays due to external factors outside the
14/LO/1428	Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study	01/12/2014		control of the Sponsor and Trust
14/SC/1269	CAIRO WPC: PROXY: Post ROSC OXYgenation Study	18/12/2014		Benchmark met
07/H0718/57	UKAITPR	18/12/2014	08/01/2015	Benchmark met
12/50/0200	CCDN2100 (Custic fibracia)	00/12/2011	17/04/2015	Descent for delay rest with the Course
13/SC/0268	CCRN2100 (Cystic fibrosis)	09/12/2014		Reasons for delay rest with the Sponsor
14/SW/1078	DRIFT School age follow-up	14/01/2015	07/02/2015	Benchmark met Delays due to external factors outside the
13/WM/0143 14/LO/1043	Study of Moxetumomab Pasudotox in pALL or LL of B-Cell LEAVO	22/01/2015 23/01/2015	16/02/2015	control of the Sponsor and Trust Benchmark met
14/YH/0085	FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab	16/01/2015		Benchmark met
	The benefit of ultrasound imaging prior to heart bypass surgery to			
14/EM/1319	prevent leg wound complications.	30/01/2015	0010-1	Benchmark met

Performance First Patient Visit Benchmark

		Project Site	Date of First	
Ethics		R&D	Patient	
Committee Ref	Project Title	Submission	Consented	Benchmark Met or Reason for Delay
13/WA/0205	AML18	10/02/2015	06/03/2015	Benchmark met
14/SC/1425	CCRN 2738 (AMD)	12/02/2015	25/02/2015	Benchmark met
				Delays due to external factors outside the
14/LO/1617	GLP110933 study Type I DM Study (DRN 3266)	06/02/2015	27/05/2015	control of the Sponsor and Trust
				Delays due to external factors outside the
14/NI/1075	CHIL3670 (ALX0171-C104)	16/02/2015		control of the Sponsor and Trust
	GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE-			
	BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND			
	SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN			
	PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE			
14/NE/1099	COLITIS WHO ARE NAIVE TO THE INHIBITORS	27/02/2015		Reasons for delay rest with the Trust
14/10/1000		27,02,2013		Delays due to external factors outside the
14/EM/0215	M12-914 Phase III Veliparib/Placebo + C/P Breast Cancer Study	02/03/2015		control of the Sponsor and Trust
14/YH/1124	EXTEND (2819MA1002)	04/03/2015		Reasons for delay rest with the Trust
14/11/1124	CHIL3846 Abbott Sensor Based Glucose Monitoring System	04/03/2013		neusons for delay rest with the trust
14/WM/1228	Paediatric Study (BEAGLE)	05/03/2015	01/04/2015	Benchmark met
				Delays due to external factors outside the
15/NW/0009	MCRN3127 (20130173)	17/03/2015	24/06/2015	control of the Sponsor and Trust
14/NW/1067	PROteKT	24/03/2015	26/06/2015	Reasons for delay rest with the Sponsor
14/1007		24/03/2013	20/00/2013	Delays due to external factors outside the
13/LO/0451	The UK TAVI Trial	07/04/2015		control of the Sponsor and Trust
12/SC/0090	Dual Erb B Inhibition in Oesophago-gastric Cancer	08/04/2015		Benchmark met
14/SC/0181	Elagolix in Endometriosis Associated Pain - Extension	10/04/2015		Benchmark met
11/SC/0173	VIABLE	28/04/2015		Benchmark met
12/EE/0368	Adrenal study	12/05/2015		Benchmark met
12/22/0500		,,		
15/LO/0104	Albumin To prevenT Infection in chronic liveR failurE (ATTIRE)	13/05/2015	03/06/2015	Benchmark met
GTAC 128	WT1 TCR-001	15/05/2015		70 days not yet reached
14/SC/1311	MCRN3165 (SD744) Cubist PSI Osteomyelitis	20/05/2015		70 days not yet reached
14/500/1016		22/04/2045	15/06/2015	Den skunsul, met
14/SW/1016	Validity of the Children's Cognitive Screening Instrument (CCOSI) An Exploratory RCT of a Psychosocial Group Intervention for	23/04/2015	15/06/2015	Benchmark met
14/WS/1149		12/06/2015		70 days not yet reached
	Epilepsy NCRN - 3245 - Betalutin radioimmunotherapy for treatment of	12/06/2015		70 days not yet reached
14/NU/1027		16/06/2015		70 days not yet reached
14/NI/1037 14/YH/1263	relapsed CD37+ NHL GLYSURE Study	16/06/2015 19/05/2015		70 days not yet reached 70 days not yet reached
15/SC/0054	CheckMate 238 (Nivolumab vs Ipilimumab in Melanoma)	22/06/2015		70 days not yet reached



3